Disclosures for "Clinical Characteristics of Creatine Transporter Deficiency (CTD): Final Results of the Vigilan Observational Study"
-
Dr. Brandabur has received personal compensation for serving as an employee of Ultragenyx. Dr. Brandabur has stock in Ultragenyx.
-
An immediate family member of Dr. Bianconi has received personal compensation for serving as an employee of Neurocrine Biosciences. An immediate family member of Dr. Bianconi has stock in Neurocrine Biosciences. An immediate family member of Dr. Bianconi has received publishing royalties from a publication relating to health care.
-
Dr. Anselm has nothing to disclose.
-
Dr. Barshop has nothing to disclose.
-
The institution of Dr. Berry-Kravis has received research support from NIH. The institution of Dr. Berry-Kravis has received research support from Ionis. The institution of Dr. Berry-Kravis has received research support from Zynerba. The institution of Dr. Berry-Kravis has received research support from Roche. The institution of Dr. Berry-Kravis has received research support from CDC. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation. The institution of Dr. Berry-Kravis has received research support from GeneTx. The institution of Dr. Berry-Kravis has received research support from Angelman Syndrome Foundation. The institution of Dr. Berry-Kravis has received research support from Acadia. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Anavex. The institution of Dr. Berry-Kravis has received research support from Rett Syndrome Research Trust. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Mallinckrodt. The institution of Dr. Berry-Kravis has received research support from Together Strong Foundation. The institution of Dr. Berry-Kravis has received research support from Orphazyme. The institution of Dr. Berry-Kravis has received research support from Taysha. The institution of Dr. Berry-Kravis has received research support from Erydel. The institution of Dr. Berry-Kravis has received research support from Tetra. The institution of Dr. Berry-Kravis has received research support from Neuren. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation.
-
Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Askbio. Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Moderna. Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sangamo. Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Koeberl has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Board of Medical Genetics and Genomics. Dr. Koeberl has stock in Askbio. The institution of Dr. Koeberl has received research support from Viking Therapeutics. The institution of Dr. Koeberl has received research support from Sangamo Therapeutics. Dr. Koeberl has received intellectual property interests from a discovery or technology relating to health care.
-
The institution of Dr. Cecil has received research support from Myrtelle, Inc..
-
Dr. Hannah-Shmouni has nothing to disclose.
-
-
Dr. Mercimek-Andrews has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ultragenyx. Dr. Mercimek-Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ultragenyx. Dr. Mercimek-Andrews has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Ultragenyx. The institution of Dr. Mercimek-Andrews has received research support from Ultragenyx.
-
The institution of Dr. Porter has received research support from NIH. The institution of Dr. Porter has received research support from Ultragenyx. Dr. Porter has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Rahhal has nothing to disclose.
-
The institution of Dr. Sutton has received research support from Ultragenyx.
-
Mrs. Blair has received personal compensation for serving as an employee of Ultragenyx. Mrs. Blair has stock in Ultragenyx.
-
Ms. Cimms has received personal compensation for serving as an employee of Ultragenyx Pharmaceutical . Ms. Cimms has stock in Ultragenyx Pharmaceutical .
-
Ms. Zhang has received personal compensation for serving as an employee of Ultragenyx Inc.
-
Cristan Farmer PhD has nothing to disclose.
-
Dr. Thurm has received personal compensation in the range of $100,000-$499,999 for serving as a Thurm with NIMH.
-
The institution of Dr. Miller has received research support from Ultragenyx.